Description

Strain Information

Former Names B6;129P2-Mecp2tm2Bird/J    (Changed: 16-SEP-09 ) B6.129P2-Mecp2tm2Bird/J    (Changed: 06-MAY-08 ) Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Mating System See Colony Maintenance under the Health & husbandry tab         (Female x Male)   20-FEB-09 Species laboratory mouse Generation N6+N16 (27-DEC-12) Generation Definitions   Donating Investigator Adrian Bird,   University of Edinburgh

Description
These mice possess a loxP-flanked STOP cassette in intron 2 of the targeted gene on the X chromosome. Western blot and hybridization analysis confirm the absence of wildtype protein from the targeted allele (although the donating investigator reports that the targeted allele produces a "read-through" transcript which does not give rise to detectable levels of protein but makes it difficult to discriminate between the "flox-stopped" and reactivated alleles by RT-PCR). Hemizygous (Mecp2^lox-Stop/y) males do not breed and develop Rett syndrome symptoms (reduced mobility, hindlimb clasping) at approximately 6 weeks of age, with death occurring at approximately 11 weeks of age. Heterozygous females are fertile until developing Rett syndrome characteristics at 4-12 months of age. This Rett syndrome-like phenotype is similar to that observed for the traditional knock-out allele (see Stock No. 003890). Cre recombinase-mediated removal of the floxed-STOP cassette restores transcription from the targeted allele and MECP2 protein activity to normal, and reverses the Rett syndrome-like neurological defects.

This mutant mouse strain may be bred to a strain expressing tamoxifen inducible Cre recombinase in most tissues (see Stock No. 004682).

Mice with this X-linked lox-STOP mutation may be useful in neurological and developmental studies of Rett syndrome and its amelioration upon excision of the lox-STOP cassette.

Development
A targeting vector was designed to insert a loxP-flanked STOP-Neo cassette into intron 2 of the targeted gene. The STOP-Neo cassette is composed of a PGK-Neo cassette followed by the 3' portion of the yeast His3 gene, an SV40 polyadenylation sequence, and a false translation initiation codon followed by a 5' splice donor site. The construct was electroporated into 129P2/OlaHsd-derived E14TG2a embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6 blastocysts, and chimeric offspring were bred to C57BL/6 mice. Heterozygous female mutants were bred to wild-type C57BL/6 males for 5 generations prior to arrival at The Jackson Laboratory. A SNP (single nucleotide polymorphism) panel analysis performed in April 2009 by The Jackson Laboratory revealed that this strain was on a mixed B6;129 genetic background background. Further backcrossing to C57BL/6J inbred mice generated mutant mice congenic on a C57BL/6 genetic background (confirmed by SNP analysis August 2009).

Control Information

	Control
	Wild-type from the colony
	100492 B6129PF1/J	(approximate)
Considerations for Choosing Controls

Related Strains

Strains carrying other alleles of Mecp2

003890	B6.129P2(C)-Mecp2tm1.1Bird/J
007177	B6.129P2-Mecp2tm1Bird/J
005439	B6.129S-Mecp2tm1Hzo/J
018282	B6.Cg-Mapttm1(Mecp2)Jae/LimmJ
006847	B6;129P2-Mecp2tm1Bird/J
017741	B6N.129(Cg)-Mecp2tm1.1Joez/J
016207	B6N.129-Mecp2tm1.1Vnar/J
012602	STOCK Mecp2tm1.1Irsf/J
014610	STOCK Mecp2tm3.1Bird/J

View Strains carrying other alleles of Mecp2     (9 strains)

Additional Web Information

Introduction to Cre-lox technology

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI

- Model with phenotypic similarity to human disease where etiologies involve orthologs. Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).

Rett Syndrome; RTT

- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested. Angelman Syndrome; AS   (MECP2) Autism, Susceptibility to, X-Linked 3; AUTSX3   (MECP2) Encephalopathy, Neonatal Severe, Due to Mecp2 Mutations   (MECP2) Lubs X-Linked Mental Retardation Syndrome; MRXSL   (MECP2) Mental Retardation, X-Linked, Syndromic 13; MRXS13   (MECP2)

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI

      assigned by genotype

The following phenotype information may relate to a genetic background differing from this JAX^® Mice strain.

Mecp2^tm2Bird/Mecp2⁺

        involves: 129P2/OlaHsd * C57BL/6

• behavior/neurological phenotype
• abnormal behavior
  • at 4 to 12 months of age, mice exhibit a progressive development of RTT-like symptoms (inertia, gait, hindlimb clasping, tremor, irregular breathing and poor general condition)   (MGI Ref ID J:118365)
• • limb grasping
    • at 4 to 12 months of age   (MGI Ref ID J:118365)
  • tremors
    • at 4 to 12 months of age   (MGI Ref ID J:118365)
• growth/size phenotype
• obese
  • mice exhibit excess weight gain   (MGI Ref ID J:118365)
• nervous system phenotype
• reduced long term potentiation
  • mice develop a reduction in long term potentiation   (MGI Ref ID J:118365)
• respiratory system phenotype
• abnormal breathing pattern
  • at 4 to 12 months of age   (MGI Ref ID J:118365)

Mecp2^tm2Bird/Y

        involves: 129P2/OlaHsd * C57BL/6

• mortality/aging
• premature death
  • male mice survive on average 11 weeks from birth   (MGI Ref ID J:118365)
• behavior/neurological phenotype
• abnormal behavior
  • during the last 4 weeks of life, mice exhibit a progressive development of RTT-like symptoms (inertia, gait, hindlimb clasping, tremor, irregular breathing and poor general condition)   (MGI Ref ID J:118365)
  • at 12 weeks mice display low stance, inertia, tremor, arrhythmic breathing, splayed himdlimb and moderate hindlimb clasping   (MGI Ref ID J:118365)
• • limb grasping
    • at 12 weeks, mice display moderate hindlimb clasping   (MGI Ref ID J:118365)
  • tremors
    • at 12 weeks   (MGI Ref ID J:118365)
• respiratory system phenotype
• abnormal breathing pattern
  • at 12 weeks   (MGI Ref ID J:118365)

The following phenotype relates to a compound genotype created using this strain.
Contact JAX^® Services jaxservices@jax.org for customized breeding options.

Mecp2^tm2Bird/Mecp2⁺ Tg(CAG-cre/Esr1*)5Amc/?

        involves: 129P2/OlaHsd * C57BL/6 * CBA   (conditional)

• behavior/neurological phenotype
• abnormal behavior
  • at 4 to 12 months of age, mice exhibit a progressive development of RTT-like symptoms (inertia, gait, hindlimb clasping, tremor, irregular breathing and poor general condition)   (MGI Ref ID J:118365)
  • however, tamoxifen treatment after the onset of symptoms reverses symptom progression   (MGI Ref ID J:118365)
• • limb grasping
    • at 4 to 12 months of age   (MGI Ref ID J:118365)
    • however, tamoxifen treatment after the onset of symptoms reverses symptom progression   (MGI Ref ID J:118365)
  • tremors
    • at 4 to 12 months of age   (MGI Ref ID J:118365)
    • however, tamoxifen treatment after the onset of symptoms reverses symptom progression   (MGI Ref ID J:118365)
• nervous system phenotype
• reduced long term potentiation
  • mice develop a reduction in long term potentiation   (MGI Ref ID J:118365)
  • however, treatment with tamoxifen returns long term potentiation to normal levels   (MGI Ref ID J:118365)
• respiratory system phenotype
• abnormal breathing pattern
  • at 4 to 12 months of age   (MGI Ref ID J:118365)
  • however, tamoxifen treatment after the onset of symptoms reverses symptom progression   (MGI Ref ID J:118365)
• growth/size phenotype
• obese
  • mice exhibit excess weight gain   (MGI Ref ID J:118365)
  • however, tamoxifen treatment after the onset of symptoms reverses weight gain   (MGI Ref ID J:118365)

Mecp2^tm2Bird/Y Tg(CAG-cre/Esr1*)5Amc/0

        involves: 129P2/OlaHsd * C57BL/6 * CBA   (conditional)

• mortality/aging
• premature death
  • 9 of 17 mice treated with tamoxifen at 3 to 4 weeks of age die soon after treatment   (MGI Ref ID J:118365)
  • however, tamoxifen-tocixity is not responsible for observed deaths, 8 of 17 mice treated with tamoxifen at 3 to 4 weeks of age have a normal life span, and mice treated with tamoxifen from week 12 to 17 exhibit normal lethality   (MGI Ref ID J:118365)
• behavior/neurological phenotype
• *normal* behavior/neurological phenotype
  • the surviving 8 of 17 mice treated with tamoxifen at 3 to 4 weeks of age exhibit normal behavior/neurological phenotypes   (MGI Ref ID J:118365)
• • abnormal behavior
    • at 12 weeks mice display low stance, inertia, tremor, arrhythmic breathing, splayed himdlimb and moderate hindlimb clasping   (MGI Ref ID J:118365)
    • during the last 4 weeks of life, mice exhibit a progressive development of RTT-like symptoms (inertia, gait, hindlimb clasping, tremor, irregular breathing and poor general condition)   (MGI Ref ID J:118365)
    • mice treated with tamoxifen at 12 to 17 weeks of age exhibit only mild RTT-like symptoms   (MGI Ref ID J:118365)
  • • limb grasping
      • at 12 weeks, mice display moderate hindlimb clasping   (MGI Ref ID J:118365)
      • mice treated with tamoxifen at 12 to 17 weeks of age exhibit only mild RTT-like symptoms   (MGI Ref ID J:118365)
    • tremors
      • at 12 weeks   (MGI Ref ID J:118365)
      • mice treated with tamoxifen at 12 to 17 weeks of age exhibit only mild RTT-like symptoms   (MGI Ref ID J:118365)
• respiratory system phenotype
• abnormal breathing pattern
  • at 12 weeks   (MGI Ref ID J:118365)
  • mice treated with tamoxifen at 12 to 17 weeks of age exhibit only mild RTT-like symptoms   (MGI Ref ID J:118365)

View Research Applications

Research Applications

This mouse can be used to support research in many areas including:

Mouse/Human Gene Homologs
Rett syndrome

Neurobiology Research
Behavioral and Learning Defects
Cre-lox System
      loxP-flanked Sequences
Neurodevelopmental Defects
      Rett's syndrome

Research Tools
Cre-lox System
      loxP-flanked Sequences
Developmental Biology Research
      Cre-lox System

Mecp2^tm2Bird related

Neurobiology Research
Ataxia (Movement) Defects

Genes & Alleles

Gene & Allele Information provided by MGI

Allele Symbol		Mecp2tm2Bird
Allele Name		targeted mutation 2, Adrian Bird
Allele Type		Targeted (Floxed/Frt)
Common Name(s)		Mecp2lox-stop; Mecp2stop;
Mutation Made By		Adrian Bird,   University of Edinburgh
Strain of Origin		129P2/OlaHsd
ES Cell Line Name		E14TG2a
ES Cell Line Strain		129P2/OlaHsd
Gene Symbol and Name		Mecp2, methyl CpG binding protein 2
Chromosome		X
Gene Common Name(s)		1500041B07Rik; AUTSX3; BB130002; D630021H01Rik; MRX16; MRX79; MRXS13; MRXSL; Mbd5; PPMX; RIKEN cDNA 1500041B07 gene; RIKEN cDNA D630021H01 gene; RS; RTS; RTT; WBP10; expressed sequence BB130002;
Molecular Note		Cre recombinase-reversible gene inactivation was accomplished by insertion into intron 2 of a 3.1-kb DNA fragment containing a loxP-flanked "neostop" cassette, which comprises a neomycin resistance cassette followed by a transcriptional/translational "stop" cassette composed of 550 bp of 3' sequence from the Saccharomyces cerevisiae His3 gene, an SV40 polyadenylation sequence, and a synthetic sequence containing a false translation initiation codon (ATG) immediately followed by a consensus splice donor sequence. Despite the production of a read-through transcript, no protein product was detected by western blot or immunofluorescence analysis of brains of mutant mice. [MGI Ref ID J:111323] [MGI Ref ID J:118365] [MGI Ref ID J:75205]

Genotyping

Genotyping Information

Genotyping Protocols

Mept2^tm2bird, Melt Curve Analysis
Mecp2^tm2Bird, Standard PCR

Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Guy J; Gan J; Selfridge J; Cobb S; Bird A. 2007. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315(5815):1143-7. [PubMed: 17289941]  [MGI Ref ID J:118365]

Additional References

Dragatsis I; Zeitlin S. 2001. A method for the generation of conditional gene repair mutations in mice. Nucleic Acids Res 29(3):E10. [PubMed: 11160912]  [MGI Ref ID J:111323]

Mecp2^tm2Bird related

Derecki NC; Cronk JC; Lu Z; Xu E; Abbott SB; Guyenet PG; Kipnis J. 2012. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 484(7392):105-9. [PubMed: 22425995]  [MGI Ref ID J:183878]

Dragatsis I; Zeitlin S. 2001. A method for the generation of conditional gene repair mutations in mice. Nucleic Acids Res 29(3):E10. [PubMed: 11160912]  [MGI Ref ID J:111323]

Kernohan KD; Jiang Y; Tremblay DC; Bonvissuto AC; Eubanks JH; Mann MR; Berube NG. 2010. ATRX partners with cohesin and MeCP2 and contributes to developmental silencing of imprinted genes in the brain. Dev Cell 18(2):191-202. [PubMed: 20159591]  [MGI Ref ID J:158584]

Lakso M; Sauer B; Mosinger B Jr; Lee EJ; Manning RW; Yu SH; Mulder KL; Westphal H. 1992. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci U S A 89(14):6232-6. [PubMed: 1631115]  [MGI Ref ID J:75205]

Lang M; Wither RG; Brotchie JM; Wu C; Zhang L; Eubanks JH. 2013. Selective preservation of MeCP2 in catecholaminergic cells is sufficient to improve the behavioral phenotype of male and female Mecp2-deficient mice. Hum Mol Genet 22(2):358-71. [PubMed: 23077217]  [MGI Ref ID J:191128]

Lioy DT; Garg SK; Monaghan CE; Raber J; Foust KD; Kaspar BK; Hirrlinger PG; Kirchhoff F; Bissonnette JM; Ballas N; Mandel G. 2011. A role for glia in the progression of Rett's syndrome. Nature 475(7357):497-500. [PubMed: 21716289]  [MGI Ref ID J:174777]

McLeod F; Ganley R; Williams L; Selfridge J; Bird A; Cobb SR. 2013. Reduced seizure threshold and altered network oscillatory properties in a mouse model of Rett syndrome. Neuroscience 231:195-205. [PubMed: 23238573]  [MGI Ref ID J:194298]

Ward CS; Arvide EM; Huang TW; Yoo J; Noebels JL; Neul JL. 2011. MeCP2 Is Critical within HoxB1-Derived Tissues of Mice for Normal Lifespan. J Neurosci 31(28):10359-70. [PubMed: 21753013]  [MGI Ref ID J:174516]

Weng SM; McLeod F; Bailey ME; Cobb SR. 2011. Synaptic plasticity deficits in an experimental model of rett syndrome: long-term potentiation saturation and its pharmacological reversal. Neuroscience 180:314-21. [PubMed: 21296130]  [MGI Ref ID J:173701]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX11

Colony Maintenance

Breeding & Husbandry	When maintaining a live colony, females heterozygous for this X-linked mutation can be bred with wildtype male siblings. The donating investigator recommends replacing heterozygous female breeders when Rett syndrome symptoms appear or when females fail to produce or care for regular litters (may be as early as 4-6 months). The donating investigator also reports that breeding performance may be improved if mice are maintained on a mixed C57BL/6;BALB/c background.
Mating System	See Colony Maintenance under the Health & husbandry tab         (Female x Male)   20-FEB-09
Diet Information	LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls

Control Information

	Control
	Wild-type from the colony
	100492 B6129PF1/J	(approximate)
Considerations for Choosing Controls
Control Pricing Information for Genetically Engineered Mutant Strains.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

See Terms of Use tab for General Terms and Conditions

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX^® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX^® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX^® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

---

Ordering Information
JAX^® Mice
Surgical and Preconditioning Services
JAX^® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use

General Terms and Conditions

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:	207-288-6470
fax:	207-288-6655

JAX^® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.